These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 3000317)

  • 1. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review.
    Arana GW; Baldessarini RJ; Ornsteen M
    Arch Gen Psychiatry; 1985 Dec; 42(12):1193-204. PubMed ID: 3000317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dexamethasone suppression test: an overview of its current status in psychiatry. The APA Task Force on Laboratory Tests in Psychiatry.
    Am J Psychiatry; 1987 Oct; 144(10):1253-62. PubMed ID: 3310667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The overnight dexamethasone suppression test: clinical and theoretical review.
    Gwirtsman H; Gerner RH; Sternbach H
    J Clin Psychiatry; 1982 Aug; 43(8):321-7. PubMed ID: 7047505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An augmented escape of androstenedione from suppression by dexamethasone in melancholia: relationships to intact ACTH and cortisol nonsuppression.
    Maes M; Van Gastel A; Blockx P; Martin M; Cosyns P; Scharpé S; Desnyder R
    J Affect Disord; 1995 Aug; 34(4):291-300. PubMed ID: 8550955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The dexamethasone suppression test in affective disorders. A review].
    Charles G; Wilmotte J; Mendlewicz J
    Acta Psychiatr Belg; 1982; 82(3):349-62. PubMed ID: 6299064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further investigation of the dexamethasone suppression test in affective illnesses: relationship to clinical diagnosis and therapeutic response.
    Mendlewicz J; Hubain PP; Koumakis C
    Neuropsychobiology; 1984; 12(1):23-6. PubMed ID: 6514175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Low-dose (0.5 mg) DST in manic and major depressive episodes: in relation to the severity of symptoms].
    Matsunaga H; Sarai M
    Seishin Shinkeigaku Zasshi; 2000; 102(4):367-98. PubMed ID: 10892305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment DST and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. A multicenter study.
    Stokes PE; Stoll PM; Koslow SH; Maas JW; Davis JM; Swann AC; Robins E
    Arch Gen Psychiatry; 1984 Mar; 41(3):257-67. PubMed ID: 6367690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma corticosterone and cortisol following dexamethasone in psychiatric patients.
    Arana GW; Wilens TE; Baldessarini RJ
    Psychoneuroendocrinology; 1985; 10(1):49-60. PubMed ID: 4001277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The DST as a predictor of outcome in depression: a meta-analysis.
    Ribeiro SC; Tandon R; Grunhaus L; Greden JF
    Am J Psychiatry; 1993 Nov; 150(11):1618-29. PubMed ID: 8214170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dexamethasone suppression and thyrotropin-releasing hormone tests and response to treatment in unipolar depression.
    Extein I; Kirstein LS; Pottash AL; Gold MS
    Int J Psychiatry Med; 1982-1983; 12(4):267-74. PubMed ID: 6820012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of adolescents with major depression: implications of the DST and the melancholic clinical subtype.
    Robbins DR; Alessi NE; Colfer MV
    J Affect Disord; 1989; 17(2):99-104. PubMed ID: 2527896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dexamethasone suppression test and depression. Approaches to the use of a laboratory test in psychiatry.
    Arana GW; Mossman D
    Neurol Clin; 1988 Feb; 6(1):21-39. PubMed ID: 2837633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical use of the dexamethasone suppression test in DSM-III affective disorders: correlation with the severe depressive subtypes of melancholia and psychosis.
    Evans DL; Nemeroff CB
    J Psychiatr Res; 1987; 21(2):185-94. PubMed ID: 3585807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic heterogeneity and the DST in consecutive psychiatric admissions.
    Keitner GI; Haier RJ; Qualls CB; Brown WA; McKendall MJ
    Psychiatry Res; 1985 Mar; 14(3):215-23. PubMed ID: 3858894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression.
    Rush AJ; Giles DE; Schlesser MA; Orsulak PJ; Weissenburger JE; Fulton CL; Fairchild CJ; Roffwarg HP
    Biol Psychiatry; 1997 May; 41(9):915-28. PubMed ID: 9110097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of antidepressant withdrawal on the dexamethasone suppression test.
    Dilsaver SC; Greden JF
    Psychiatry Res; 1985 Feb; 14(2):11-22. PubMed ID: 3857651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of early and delayed inpatient dexamethasone suppression tests.
    Haskett RF; Zis AP; Albala AA; Lohr NE; Carroll BJ
    Psychiatry Res; 1989 Feb; 27(2):161-71. PubMed ID: 2710864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dexamethasone suppression test in psychiatry.
    Joyce PR; Brinded PJ; Sellman D; Donald RA; Elder PA
    N Z Med J; 1987 Mar; 100(820):173-5. PubMed ID: 3452036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of the dexamethasone test in the differential diagnosis of depressive states].
    Nuller IuL; Ostroumova MN; Gordon OI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(4):547-51. PubMed ID: 3716705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.